DCT

1:26-cv-01175

ViiV Healthcare Co v. Aurobindo Pharma Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: ViiV Healthcare Co. v. Aurobindo Pharma Ltd., 1:26-cv-01175, D. Del., 09/18/2026
  • Venue Allegations: Venue is asserted based on Defendants' business activities, including the marketing and sale of generic pharmaceuticals within Delaware, and Aurobindo USA's incorporation in the state.
  • Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) for a generic version of the HIV-1 drug TRIUMEQ® constitutes an act of infringement of a patent claiming a specific crystalline form of dolutegravir sodium, one of the drug's active ingredients.
  • Technical Context: The technology concerns a specific crystalline solid-state form (polymorph) of dolutegravir sodium, an active pharmaceutical ingredient. Control over a drug's crystalline form is critical for ensuring consistent solubility, stability, and bioavailability in pharmaceutical manufacturing and performance.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following Plaintiffs' receipt of a Paragraph IV Notice Letter from Defendants, dated August 5, 2026. In the letter, Defendants sought FDA approval to market a generic product prior to the expiration of the asserted patent, certifying that the patent is invalid, unenforceable, and/or will not be infringed. The patent has been granted pediatric exclusivity, extending its expiration to June 8, 2030.

Case Timeline

Date Event
2008-12-11 Priority Date for U.S. Patent No. 9,242,986
2016-01-26 U.S. Patent No. 9,242,986 Issued
2026-08-05 Date of Defendants' Paragraph IV Notice Letter
2026-09-18 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,242,986 - "Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates"

  • Patent Identification: U.S. Patent No. 9,242,986 (“the ’986 Patent”), titled “Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates,” issued on January 26, 2016. Compl. ¶20

The Invention Explained

  • Problem Addressed: While the patent's background section discusses various chemical synthesis pathways for HIV integrase inhibitors, the claimed invention addresses the distinct pharmaceutical problem of creating a specific, stable, and reproducible solid form of the active pharmaceutical ingredient dolutegravir. Compl. ¶27 '986 Patent, col. 1:11-34 The properties of a drug's solid form are critical for its formulation into a safe and effective medicine.
  • The Patented Solution: The ’986 Patent claims specific crystalline forms of the sodium salt of a compound designated "formula AA" (dolutegravir), not a method of synthesis. Compl. ¶27 ’986 Patent, claims 1, 7 These crystalline forms are defined by their unique physical "fingerprints" as measured by X-ray powder diffraction (XRPD), which produces a pattern of characteristic peaks. ’986 Patent, col. 9:43-52 '986 Patent, FIG. 1 '986 Patent, FIG. 4 The patent discloses that these specific forms possess advantageous properties, such as high solubility and stability, which are desirable for a pharmaceutical product. '986 Patent, col. 12:52-59
  • Technical Importance: Obtaining patent protection on a specific polymorph of a drug is a key strategy in the pharmaceutical industry, as it can provide market exclusivity for a successful drug product even after the patent on the base chemical compound has expired.

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims and specifically notes that Defendants' notice letter allegedly does not dispute infringement of claims 1-6, but challenges their validity. Compl. ¶31 Compl. ¶37 The two independent claims are Claim 1 and Claim 7.
  • Independent Claim 1 recites:
    • A crystal form of a sodium salt of a compound of formula AA
    • having characteristic diffraction peaks at 6.4°±0.2°, 9.2°±0.2°, 13.8°±0.2°, 19.2°±0.2° and 21.8°±0.2° degrees two-theta in an X-ray powder diffraction pattern.
  • Independent Claim 7 recites:
    • A crystal form of a hydrate of a sodium salt of a compound of formula AA
    • having characteristic diffraction peaks at 8.0°±0.2°, 9.3°±0.2°, 11.3°±0.2°, 16.0°±0.2°, and 22.8°±0.2° degrees two-theta in an X-ray powder diffraction pattern.

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendants' "Proposed ANDA Product," identified as a generic version of ViiV's TRIUMEQ® tablets. Compl. ¶10 The product is a fixed-dose combination tablet containing abacavir sulfate, lamivudine, and dolutegravir sodium. Compl. ¶10

Functionality and Market Context

  • The Proposed ANDA Product is intended to be a generic equivalent for TRIUMEQ®, which is an FDA-approved treatment for HIV-1 infection. Compl. ¶10 Compl. ¶21 The infringement allegation centers on the dolutegravir sodium component of the proposed generic product. Compl. ¶27
  • The complaint states that Defendants' ANDA No. 210642 relies on data demonstrating the bioequivalence of the Proposed ANDA Product to Plaintiffs' approved TRIUMEQ® product. Compl. ¶28 The filing of the ANDA is the statutory act of infringement that gives rise to this lawsuit. Compl. ¶32

IV. Analysis of Infringement Allegations

The complaint does not contain a claim chart. Instead, its infringement theory relies heavily on alleged statements made by the Defendants in their Paragraph IV Notice Letter.

The core allegation is that the dolutegravir sodium active pharmaceutical ingredient that "is and/or will be present in the Proposed ANDA Product" is the specific crystalline form covered by one or more claims of the ’986 Patent. Compl. ¶27 The complaint asserts that Defendants' submission of ANDA No. 210642 for the purpose of marketing this product before the patent's expiration constitutes infringement under 35 U.S.C. § 271(e)(2). Compl. ¶32

Crucially, the complaint alleges that "In the Notice Letter, Defendants do not dispute that the Proposed ANDA Product will infringe Claims 1-6 of the '986 Patent unless Claims 1-6 of the '986 Patent are found invalid." Compl. ¶37 This frames the primary dispute as one of patent validity rather than factual infringement for those claims. The complaint further alleges that Defendants' assertion of non-infringement for claims 7-12 was made without a good faith basis. Compl. ¶40

No probative visual evidence provided in complaint.

  • Identified Points of Contention:
    • Validity vs. Infringement: The complaint's allegation of an admission suggests the central legal battle may be over the validity of claims 1-6, rather than whether the accused product infringes them. Defendants will likely argue that the claimed crystal form is obvious over or anticipated by the prior art.
    • Technical Question (Polymorphic Form): A foundational technical question is which, if any, crystalline form of dolutegravir sodium is used in Defendants' product. The dispute may involve comparing the physical properties (e.g., XRPD data) of Defendants' drug substance with the properties recited in both the anhydrate form of Claim 1 and the hydrate form of Claim 7.
    • Scope Question: The scope of the claims hinges on the meaning of "characteristic diffraction peaks" and the significance of the "±0.2°" tolerance. The court may need to determine if an accused product must show all the listed peaks, and how to treat an accused product that has the listed peaks plus additional, unlisted peaks.

V. Key Claim Terms for Construction

  • The Term: "characteristic diffraction peaks at [list of peak positions] degrees two-theta"
  • Context and Importance: This term defines the patented invention. In pharmaceutical patent litigation involving polymorphs, the entire infringement analysis rests on comparing instrumental data from the accused product to the claimed data. Practitioners may focus on this term because any ambiguity in its meaning—such as what makes a peak "characteristic" or the exact scope of the ±0.2° error margin—could be outcome-determinative.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: Plaintiffs may argue that the term "characteristic" implies that the listed peaks are the most representative or essential identifiers of the crystal form, but not necessarily the only peaks that may be present. The inclusion of a tolerance range (±0.2°) in the claim language itself explicitly accounts for minor experimental variation, supporting an interpretation that does not require a perfect, identical match to the reference pattern. '986 Patent, claim 1
    • Evidence for a Narrower Interpretation: Defendants may argue that the claim is limited to a crystal form that substantially matches the patterns depicted in the patent's figures. '986 Patent, FIG. 1 '986 Patent, FIG. 4 They might contend that the term "having" means the claimed form must, at a minimum, possess all the recited peaks, and that the presence of different peaks or the absence of a recited peak places their product outside the claim's scope.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon approval, Defendants will induce infringement by providing product labeling and instructions that direct physicians and patients to use the Proposed ANDA Product in an infringing manner. Compl. ¶29 Compl. ¶33
  • Willful Infringement: The complaint does not use the term "willful infringement" but does request a declaration that the case is "exceptional under 35 U.S.C. § 285," which allows for the recovery of attorneys' fees. Compl. ¶40 The basis for this allegation is the assertion that Defendants "lacked a good faith basis" for their Paragraph IV certification, specifically regarding their invalidity challenge to claims 1-6 and their non-infringement assertion for claims 7-12. Compl. ¶40 The complaint also alleges Defendants had knowledge of the patent when they filed their ANDA. Compl. ¶26 Compl. ¶38

VII. Analyst’s Conclusion: Key Questions for the Case

Based on the complaint, the litigation appears poised to center on two primary questions for the court:

  • A question of law and fact regarding patent validity: The complaint frames the core of the dispute as a challenge to the validity of the ’986 Patent, stemming from Defendants' alleged concession of infringement for claims 1-6. The case will likely involve a detailed examination of the prior art to determine if the claimed crystalline form of dolutegravir sodium was novel and non-obvious at the time of the invention.
  • An evidentiary question of polymorphic identity: Should the validity of the patent be upheld, a key factual issue will be whether the dolutegravir sodium in Defendants' generic product is, in fact, the anhydrate crystalline form of Claim 1 or the hydrate form of Claim 7. This will require a side-by-side comparison of analytical data from Defendants' product against the specific XRPD peak limitations recited in the patent claims.